Recent evidence indicates that in prostate cancer, the mocetinostat, a class I selective inhibitor of the HDACs, up-regulates miR-31 with consequent loss of expression of its target E2F transcription factor 6 (E2F6), induction of apoptosis, and reduction in cancer growth [114]. Here, E2F6 is linked to prostate carcinoma.